Close

CCP

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cyclic citrullinated peptide: A circular peptide containing the amino acid citrulline. Abbreviated CCP. Autoantibodies directed against CCP are found in people with rheumatoid arthritis.
  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAART-LX015 Anti-CCP (X6X73) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X73 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX016 Anti-CCP (X6X74) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X74 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX017 Anti-CCP (X6X75) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X75 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX018 Anti-CCP (X6X69) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X69 Mouse scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX019 Anti-CCP (X6X76) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X76 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX020 Anti-CCP (X6X70) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X70 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX021 Anti-CCP (X6X71) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X71 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX022 Anti-CCP (X6X72) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X72 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX023 Anti-CCP (X6X77) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X77 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX024 Anti-CCP (X6X78) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X78 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX025 Anti-CCP (X6X79) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X79 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX026 Anti-CCP (X6X80) h(CD28-CD3ζ) CAART, pCDCAAR1 Human X6X80 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX027 Anti-CCP (X6X73) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X73 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX028 Anti-CCP (X6X74) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X74 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX033 Anti-CCP (X6X71) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X71 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX034 Anti-CCP (X6X72) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X72 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX035 Anti-CCP (X6X77) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X77 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX036 Anti-CCP (X6X78) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X78 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX037 Anti-CCP (X6X79) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X79 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX038 Anti-CCP (X6X80) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human X6X80 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.